Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement

Journal of Clinical Gastroenterology

Volumn 32, Issue 2, 2001, Pages 123-127

  Gonzalez, Robinson ^a,b   Storr, Martin ^a,b   Bloching, Herbert ^a,b   Seige, Markus ^a,b   Ott, Roland ^a,b   Allescher, Hans Dieter ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Rheumaklink Oberammergau   (Germany)

Author keywords

Autoantibodies; Esophageal motility; Progressive systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ESOPHAGUS DISEASE; ESOPHAGUS MOTILITY; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MANOMETRY; PRIORITY JOURNAL; SKELETAL MUSCLE; SYSTEMIC SCLEROSIS;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; CENTROMERE; CREST SYNDROME; ESOPHAGEAL MOTILITY DISORDERS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PERISTALSIS; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 0035154371     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200102000-00006     Document Type: Article

References (42)

1. Progressive systemic sclerosis (scleroderma)
2. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma
3. The gastrointestinal manifestations of scleroderma: Pathogenesis and management
4. Esophageal motility in patients with scleroderma and related diseases
5. Esophageal motor abnormalities in scleroderma and related diseases
6. Progressive systemic sclerosis. Gastrointestinal involvement
7. Esophageal manometry and pH-probe monitoring in the evaluation of gastroesophageal reflux in patients with progressive systemic sclerosis
8. Surgical management of benign stricture from reflux esophagitis
9. Scleroderma and esophageal reflux, surgical monitoring
10. Esophagitis in scleroderma. Prevalence and risk factors
11. Esophagitis in progressive systemic scleroderma. Prevalence and risk factors in forty-six patients
12. Esophageal manometry in scleroderma
13. Esophageal function in systemic sclerosis: A prospective evaluation of motility and acid reflux in 36 patients
14. Skeletal muscle involvement in progressive systemic sclerosis (PSS)
15. Muscle diseases in progressive systemic sclerosis: Diagnostic and therapeutic considerations
16. Progressive systemic sclerosis: Mode of presentation, rapidly progressive disease course and mortality based on analysis of 91 patients
17. Oropharyngeal and esophageal function in scleroderma
18. Esophageal motility in progressive systemic sclerosis (PSS)
19. Comparative studies of esophageal function in systemic sclerosis
20. Sequential dermal microvascular and perivascular changes in the development of scleroderma
21. Immunologic aspects of scleroderma
22. Systemic sclerosis (Scleroderma) and mixed connective tissue disease
23. Autoantibodies in the diagnosis of systemic rheumatic diseases
24. Antinuclear antibodies and the connective tissue disease
25. Antinuclear antibodies: An overview
26. Clinical significance of antinuclear antibodies in japanese patients with systemic sclerosis
27. Clinical correlation of anticentromere antibodies
28. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis
29. Anticentromere antibody as a predictor of ischemic loss in patients with systemic sclerosis
30. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone
31. Autoantibodies in scleroderma
32. SCL86 a marker antigen for diffuse scleroderma
33. Preliminary criteria for the classification of systemic sclerosis. Subcommittee for scleroderma criteria of the American Rheumatism Association
34. Laboratory evaluation of rheumatic diseases
35. Immunologic parameters in systemic sclerosis
36. Associations of anti-UIRNP and Scl-70 antibodies with neurologic manifestations in systemic sclerosis
37. Clinical and prognostic associations based on serum antinuclear antibodies in japanese patients with systemic sclerosis
38. Anticentromere antibody: Clinical associations: A study of 44 patients
39. Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants
40. Clinical and Laboratory associations of anticentromere antibodies in patients with progressive systemic sclerosis
41. Gastrointestinal manifestations of systemic sclerosis
42. Autoantibody profiles predict esophageal involvement in patients with progressive systemic sclerosis (PSS)